ID   KTOR2-RE
AC   CVCL_E6D9
RX   PubMed=31900393;
CC   Population: Japanese.
CC   Sequence variation: Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK; Note=E13A20 v1 fusion (PubMed=31900393).
CC   Sequence variation: Mutation; HGNC; HGNC:427; ALK; Simple; p.Leu1196Met (c.3586C>A); ClinVar=VCV000376135; Zygosity=Unspecified (PubMed=31900393).
CC   Donor information: Established from the patient after relapse and acquired resistance to ALK inhibitors (PubMed=31900393).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C2926; Lung non-small cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_E6D8 ! KTOR2
SX   Male
AG   76Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=31900393; DOI=10.1038/s41467-019-13771-5; PMCID=PMC6941996;
RA   Tsuji T., Ozasa H., Aoki W., Aburaya S., Yamamoto Funazo T., Furugaki K.,
RA   Yoshimura Y., Yamazoe M., Ajimizu H., Yasuda Y., Nomizo T., Yoshida H.,
RA   Sakamori Y., Wake H., Ueda M., Kim Y.H., Hirai T.;
RT   "YAP1 mediates survival of ALK-rearranged lung cancer cells treated
RT   with alectinib via pro-apoptotic protein regulation.";
RL   Nat. Commun. 11:74.1-74.16(2020).
//